A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis

International Journal of MS Care

Volumn 16, Issue 3, 2014, Pages 153-160

  Goodman, Andrew D ^a   Brown, Theodore R ^b   Schapiro, Randall T ^c   Klingler, Michael ^d   Cohen, Ron ^d   Blight, Andrew R ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Evergreen Hospital Medical Center   (United States)

^c Minneapolis Clinic of Neurology   (United States)

^d ACORDA THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84908400011     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2013-023     Document Type: Article

References (35)

1. Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther. 2006;28:445-460.
2. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010;9:1182-1199.
3. Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. Neurol Clin. 2011;29:449-463.
4. de Sa JC, Airas L, Bartholome E, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011;4:139-168.
5. Ampyra [package insert]. Ardsley, NY: Acorda Therapeutics, Inc; 2013.
6. Australian Government, Department of Health and Aging, Therapeutic Goods Administration. Australian Public Assessment Report for Fampridine. http://www.tga.gov.au/pdf/auspar/auspar-fampyra.pdf. Accessed August 30, 2012.
7. European Medicines Agency Committee for Medicinal Products for Human Use. Summary of Opinion (Initial Authorisation) for Fampyra (Fampridine). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002097/WC500106531.pdf. Accessed September 18, 2012.
8. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997;48:817-821.
9. Vollmer T, Blight AR, Henney HR. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, followup study. Clin Ther. 2009;31:2215-2223.
10. Vollmer T, Henney HR. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a phase I-II, open-label trial. Clin Ther. 2009;31:2206-2214.
11. Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373:732-738.
12. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68:494-502.
13. Goodman AD, Brown TR, Cohen JA, et al. Dose-comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71:1134-1141.
14. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003;60:31-36.
15. Kalkers NF, de Groot V, Lazeron RH, et al. MS functional composite: relation to disease phenotype and disability strata. Neurology. 2000;54:1233-1239.
16. Rudick RA, Cutter G, Reingold S. The Multiple Sclerosis Functional Composite; a new clinical outcome measure for multiple sclerosis clinical trials. Mult Scler. 2002;8:359-365.
17. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871-882.
18. Cohen JA, Fischer JS, Bolibrush DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology. 2000;54:802-806.
19. Schwid SR, Goodman AD, Mattson DH, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology. 1997;49:1419-1424.
20. Bethoux FA, Bennett SE. Evaluating walking mobility in patients with multiple sclerosis: utility of instruments in clinical trials and clinical practice. Int J MS Care. 2011;13:4-14.
21. Gijbels D, Dalgas U, Romberg A, et al. Which walking capacity tests to use in multiple sclerosis? a multicentre study providing the basis for a core set. Mult Scler. 2011;18:364-371.
22. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000;6:286-290.
23. Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology. 2002;58:1294-1296.
24. Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler. 2006;12:594-598.
25. van Winsen LM, Kragt JJ, Hoogervorst EL, Polman CH, Uitdehaag BM. Outcome measurement in multiple sclerosis: detection of clinically relevant improvement. Mult Scler. 2010;16:604-610.
26. Bosma LV, Kragt JJ, Brieva L, et al. Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? Mult Scler. 2010;16:862-867.
27. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540-542.
28. Medical Research Council (MRC). Aids to the Investigation of Peripheral Nerve Injuries. London, United Kingdom: Her Majesty's Stationery Office; 1976.
29. Kryscio RJ. Fampridine for MS responders: clinically relevant or hypothesis generating? [comment]. Neurology. 2008;71:1130-1131.
30. Coleman CI, Sobieraj DM, Marinucci LN. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin. 2012;28:49-56.
31. Hobart J. Prolonged-release fampridine for multiple sclerosis: was the effect on walking ability clinically significant? [abstract]. Mult Scler. 2010;(suppl 16):S72.
32. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256: 568-576.
33. Rinon A, Buch M, Holley D, Verdun E. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629-643.
34. Margolis JM, Fowler R, Johnson BH, Kassed CA, Kahler K. Diseasemodifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. BMC Neurol. 2011;11:122.
35. Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin. 2011;27:1415-1423.